NCT02555904

Brief Summary

This is an observational, single center study to evaluate if acoustic and accelerometer-based measures of voice and speech have sufficient precision to detect a change in lung fluid status for patients with confirmed acute heart failure syndrome with pulmonary congestion. The study shall be conducted in concordance with the United States FDA regulations for a non-significant risk study. Patients admitted for acute heart failure syndrome with pulmonary congestion with an expected stay greater than 3 to 4 days, who are willing and able to sign an informed consent, and who meet all inclusion/exclusion criteria, as identified by the clinical investigator, will be enrolled in the study. Results of this study will evaluate the sensitivity of voice and speech measures in detecting changes in lung fluid status in a symptomatic population. Up to 12 subjects will be enrolled to comparatively evaluate the voice outcome measures in this pilot study.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
12

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Oct 2015

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 18, 2015

Completed
4 days until next milestone

First Posted

Study publicly available on registry

September 22, 2015

Completed
9 days until next milestone

Study Start

First participant enrolled

October 1, 2015

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2016

Completed
Last Updated

September 22, 2015

Status Verified

September 1, 2015

Enrollment Period

5 months

First QC Date

September 18, 2015

Last Update Submit

September 18, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • Relationship between change in pitch and change in total body water

    correlation of change in fundamental frequency with change in weight

    10 days

Secondary Outcomes (2)

  • relationship between change in pitch and change in NTproBNP

    10 days

  • correlation in change in pitch with change in dyspnea visual analog scale (DVAS)

    10 days

Study Arms (1)

Heart failure syndrome & pulmonary congestion

Patients who are admitted for inpatient management with acute heart failure syndrome with pulmonary congestion who require intravenous diuretics are potential candidates for the study and shall be screened for suitability based on the inclusion and exclusion criteria.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with acute heart failure syndromes admitted for inpatient management meeting inclusion and exclusion criteria will be asked to consent for the study.

You may qualify if:

  • \> 18 years
  • Prior diagnosis of heart failure with daily use of loop diuretic
  • Must be identified within 48 hrs of admission
  • Diagnosis of acute Congestive Heart Failure (CHF) as defined by at least one symptom or one clinical sign
  • Believed to be \> 10 lbs above target weight
  • Anticipated need for iv loop diuretic for at least 48 hrs

You may not qualify if:

  • Inability to perform VA
  • Respiratory infection
  • Significant pulmonary disease requiring the use of inhaler bronchodilators or steroids
  • Anticipate need for vasoactive agent or ultrafiltration
  • Systolic BP \< 90 mmHg
  • Serum Cr \> 3 on admission or requirement for dialysis
  • Hemodynamically significant arrhythmias
  • Acute Coronary Syndrome (ACS) within 4 weeks
  • Hypertrophic Obstructive Cardiomyopathy (HOCM)
  • Severe stenotic valve disease
  • Complex congenital heart disease
  • Sepsis
  • Active smoking within 1 year
  • O2 saturation less than 92% on room air
  • History of diagnosed vocal cord pathology / dysfunction

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Heart Failure

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular Diseases

Study Officials

  • Marc Semigran, MD

    Massachusetts General Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Maureen Daher, RN

CONTACT

Marc Semigran, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Physician investigator

Study Record Dates

First Submitted

September 18, 2015

First Posted

September 22, 2015

Study Start

October 1, 2015

Primary Completion

March 1, 2016

Study Completion

March 1, 2016

Last Updated

September 22, 2015

Record last verified: 2015-09